There are several clinically relevant implications for the current findings. A bidirectional causal link between psychotic disorders and cannabis use suggests public efforts to reduce cannabis use, in individuals at high risk and patients, may prevent psychotic disorders and potentially reduce psychotic symptoms for a subset of the population. Moreover, the underlying genetic component that contributes to the co-occurrence of psychotic disorders and cannabis use suggests a subgroup of individuals are at high genetic risk for psychosis and cannabis use. Early identification of this subgroup is important for targeted interventions and our results suggest polygenic risk scores may help with this risk stratification and treatment in the future.
